BRAF and neoplasm: While the use of cfDNA for post-treatment surveillance has the advantage of the availability of somatic mutations in the resected tumor, if it were to become a sensitive diagnostic tool, expanded panels of genetic mutations would need to be detected to avoid false negatives in BRAF negative caners.